<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02028312</url>
  </required_header>
  <id_info>
    <org_study_id>CEI.HER-002</org_study_id>
    <nct_id>NCT02028312</nct_id>
  </id_info>
  <brief_title>A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edward Holland, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Holprovision</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pilot study to evaluate the impact of Lotemax® Gel (loteprednol etabonate ophthalmic gel
      0.5%) on the initiation of Restasis® (cyclosporine ophthalmic emulsion 0.05%) therapy in
      subjects with dry eye.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Per Sponsor
  </why_stopped>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fluorescein corneal staining scores</measure>
    <time_frame>60 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lissamine green conjunctival staining</measure>
    <time_frame>60 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Dry Eye Disease</condition>
  <arm_group>
    <arm_group_label>Loteprednol etabonate + Restasis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Loteprednol Etabonate Ophthalmic Gel 0.5%, BID 30 days Restasis, BID 45 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Artificial Tears + Restasis</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Artificial Tears, BID 30 days Restasis, BID 45 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loteprednol etabonate</intervention_name>
    <arm_group_label>Loteprednol etabonate + Restasis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artificial Tears</intervention_name>
    <arm_group_label>Artificial Tears + Restasis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Restasis</intervention_name>
    <arm_group_label>Loteprednol etabonate + Restasis</arm_group_label>
    <arm_group_label>Artificial Tears + Restasis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provide written informed consent prior to any study-related procedures and provide
             Health Insurance Portability and Accountability Act (HIPAA) authorization.

          2. Are between the ages of 21 and 80 inclusive.

          3. Have not worn contact lenses for at least 1 month prior to the study and agrees not to
             wear contact lenses during the study.

          4. Have been on stable oral medications for 1 month prior to the study.

          5. Are in generally good and stable overall health.

          6. Are a woman of child bearing potential (WOCBP) who is not pregnant or lactating and
             not sexually active (i.e. abstinent) at Visit 1 and willing to remain so through Visit
             4. Alternatively, a WOCBP who is not abstinent must have been using an acceptable
             method of birth control for at least 4 weeks prior to Visit 1 and throughout the
             study.

          7. Are women who have undergone one of the following sterilization procedures at least 1
             month prior to Visit 1:

               1. Bilateral tubal ligation

               2. Hysterectomy

               3. Hysterectomy with unilateral or bilateral oophorectomy.

               4. Bilateral oophorectomy

          8. Are likely to comply with the eye drop regime, study guidelines, and study visits.

        Exclusion Criteria:

          1. Have a history of Stevens-Johnson Syndrome or ocular pemphigoid.

          2. Have had punctual plugs inserted or removed; or punctual cautery 3 months prior to
             Visit 1/Screening and Baseline Visit and throughout the study.

          3. Have had intra-ocular surgery within 6 months prior to the Visit 1/Screening and
             Baseline Visit.

          4. Have a history of liver disease.

          5. Be pregnant or lactating.

          6. Have severe clinical vitamin deficiencies or a history of vitamin overdose.

          7. Have a highly variable vitamin intake.

          8. Wear contact lenses.

          9. Have unstable use of systemic or topical medications known to create dry eye.

         10. Have corneal pathology, which could, of itself, cause an ocular surface disorder.

         11. Have used glaucoma medications, topical or oral within 30 days of Visit 1/Screening
             and Baseline Visit.

         12. Have unstable diabetes mellitus.

         13. Have an allergy or sensitivity to Lotemax® Gel, Restasis®, or non-preservative
             artificial tears.

         14. Have used topical steroids or Restasis® within 1 month prior to the Screening and
             Baseline Visit and throughout the study, except the study medication provided per the
             protocol.

         15. Have a condition for which steroid use would be contraindicated (e.g. viral
             infection).

         16. Use other topical ocular agents other than tear replacements within 1 week prior to
             the Screening and Baseline Visit and throughout the study.

         17. Have been exposed to an investigational drug within the preceding 30 days.

         18. In the opinion of the investigator or study coordinator, be unwilling or unable to
             comply with the study protocol or unable to successfully instill eye drops.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cincinnati Eye Institute</name>
      <address>
        <city>Edgewood</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2014</study_first_submitted>
  <study_first_submitted_qc>January 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2014</study_first_posted>
  <last_update_submitted>March 17, 2015</last_update_submitted>
  <last_update_submitted_qc>March 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Holprovision</investigator_affiliation>
    <investigator_full_name>Edward Holland, MD</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>Dry Eye</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lubricant Eye Drops</mesh_term>
    <mesh_term>Loteprednol Etabonate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

